NLS Intellectual Property

Swedish biotech company Salipro Biotech has announced that the European Patent Office has issued the European Patent titled “Saposin lipoprotein particles and libraries from crude membranes”. The patent covers the company’s novel method of direct extraction of membrane proteins (DirectMXTM) from cells or crude membranes to enable drug development for challenging drug targets, as well […]

Ilya Pharma has announced that the European Patent Office has issued the company European Patent titled “Methods for Wound Healing”. The patent covers the use of the lactic acid bacteria Lactobacillus reuteri, which have been transformed with a plasmid capable of expressing a wound healing protein selected from CXCL12, CXCL17 and Ym1 to heal cutaneous […]

BioArctic has announced that the European Patent Office (EPO) has issued a decision to grant the European patent for novel antibodies that could be developed into a treatment for Alzheimer’s disease. The antibodies target a shorter (truncated) form of amyloid beta (pE3-Aβ) and are linked to the company’s project AD1503. The patent enters into force […]

The molecular diagnostics firm Elypta announced that it has been granted a patent by the United States Patent and Trademark Office for its novel liquid biopsy method for cancer diagnostics. The patent concerns a method for screening for renal cell carcinoma, the most common form of kidney cancer, by measuring specific metabolites – glycosaminoglycans (GAGs) […]

Follicum has announced that the European Patent Office (EPO) has approved a patent which refers to the company’s novel peptides that are being developed to treat diabetes. The approval follows the previous provisional approval by the EPO announced on March 20, 2020. The approval provides protection for the company’s peptides and their use to treat […]

Orexo has announced that the US Patent and Trademark Office has issued an additional patent for ZUBSOLV, Orexo’s sublingual buprenorphine and naloxone tablet (CII) for the treatment of opioid use disorder. The new patent, US Patent No. 10,874,661, expires in September 2032 and further strengthens the company´s intellectual property for ZUBSOLV in the US. Orexo […]